Patients with nAMD more likely to discontinue longer interval anti-VEGF treatments

Contrary to expectations, more patients with neovascular age-related macular degeneration undergoing longer interval anti-VEGF therapy discontinued treatment compared with those on shorter interval treatment, according to a study.
While 76.8% of patients on a 4-week interval regimen remained on treatment at 60 months following study entry, only 60.6% of those on 12-week or longer interval regimens remained on treatment. The overall rate of discontinuation from 24 months to 60 months was 30.4%, Sophie J. Bakri, MD, chair of ophthalmology at the Mayo Clinic, and colleagues wrote in the American

Contrary to expectations, more patients with neovascular age-related macular degeneration undergoing longer interval anti-VEGF therapy discontinued treatment compared with those on shorter interval treatment, according to a study.
While 76.8% of patients on a 4-week interval regimen remained on treatment at 60 months following study entry, only 60.6% of those on 12-week or longer interval regimens remained on treatment. The overall rate of discontinuation from 24 months to 60 months was 30.4%, Sophie J. Bakri, MD, chair of ophthalmology at the Mayo Clinic, and colleagues wrote in the American